Long-acting bronchodilator use after hospitalization for COPD: an observational study of health insurance claims data.
BACKGROUND
Treatment of stable chronic obstructive pulmonary disease (COPD) with long-acting bronchodilator (LABD) medications is recommended by the 2014 Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines. The primary objective of this study was to examine LABD prescription fills after a COPD-related hospitalization.


METHODS
This retrospective observational study used claims from Truven Health MarketScan(®) Commercial and Medicare Supplemental databases. Patients (age ≥40, commercial; age ≥65, Medicare supplemental) had a first hospitalization with a primary COPD diagnosis between April 1, 2009 and June 30, 2011 (index hospitalization) and were continuously enrolled for 1 year before and 9 months after hospitalization. Patients were categorized according to pre-index and/or post-index pharmacy claims.


RESULTS
A total of 27,738 patients had an index hospitalization and met inclusion/exclusion criteria. Of those, 19,783 patients had COPD as a primary or secondary diagnosis during the year before index hospitalization and were included in the analysis. Approximately one quarter of the patients (26.32%) did not fill a prescription for an LABD or short-acting bronchodilator both 90 days before and 90 days after hospitalization. During the 90-day pre-index period, 40.57% of patients filled an LABD (with or without a short-acting bronchodilator) prescription. Over half of the patients (56.88%) filled an LABD prescription at some point during the 180-day post-index period, but, of those, a significantly greater proportion of patients filled an LABD prescription in the 1- to 90-day post-index period than in the 91- to 180-day post-index period (51.27% versus 43.66%; P<0.0001).


CONCLUSIONS
A significant proportion of COPD patients in this study did not fill an LABD prescription before hospitalization for COPD. Moreover, hospitalization did not appear to greatly impact LABD initiation. Lastly, patients who did not fill an LABD prescription within the first 90 days posthospitalization were not likely to fill an LABD prescription later. Taken together, the results of this study suggest that many patients with COPD are undertreated.
Pfizer Inc., New York, NY, USA.
Christine L
CL
Baker
Pfizer Inc., New York, NY, USA.
Kelly H
KH
Zou
Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Jun
J
Su
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D011307:Drug Prescriptions; D017723:Drug Utilization Review; D005260:Female; D019983:Guideline Adherence; D006760:Hospitalization; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D006278:Medicare; D008875:Middle Aged; D010351:Patient Discharge; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
D001993:Bronchodilator Agents
chronic obstructive pulmonary disease; non-interventional; retrospective; short-acting bronchodilator